Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Pulmonary hypertension in infants with bronchopulmonary dysplasia

  • Kim, Gi-Beom (Department of Pediatrics, Seoul National University Children's Hospital)
  • Received : 2010.05.02
  • Accepted : 2010.05.13
  • Published : 2010.06.15
Download PDF
⟨ Previous Next ⟩

Abstract

An increase in the number of preterm infants and a decrease in the gestational age at birth have resulted in an increase in the number of patients with significant bronchopulmonary dysplasia (BPD) and secondary pulmonary hypertension (PH). PH contributes significantly to the high morbidity and mortality in the BPD patients. Therefore, regular monitoring for PH by using echocardiography and B-type natriuretic peptide (BNP) or N-terminal-proBNP must be conducted in the BPD patients with greater than moderate degree to prevent PH and to ensure early treatment if PH is present. In the BPD patients with significant PH, multi-modality treatment, including treatment for correcting an underlying disease, oxygen supply, use of diverse selective pulmonary vasodilators (inhaled nitric oxide, inhaled prostacyclins, sildenafil, and endothelin-receptor antagonist) and other methods, is mandatory.

Keywords

References

  1. Northway WH, Jr., Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967;276:357-68. https://doi.org/10.1056/NEJM196702162760701
  2. Charafeddine L, D'Angio CT, Phelps DL. Atypical chronic lung disease patterns in neonates. Pediatrics 1999;103:759-65. https://doi.org/10.1542/peds.103.4.759
  3. Stevenson DK, Wright LL, Lemons JA, Oh W, Korones SB, Papile LA, et al. Very low birth weight outcomes of the National Institute of Child Health and Human Development Neonatal Research Network, January 1993 through December 1994. Am J Obstet Gynecol 1998;179:1632-9. https://doi.org/10.1016/S0002-9378(98)70037-7
  4. Sung KH, Kim MH, Kim ER, Shim JW, Lee JJ, Im JW, et al. Epidemiology of bronchopulmonary dysplasia in Korea: multi-center study. Korean J Perinatol 2009;20:225-33.
  5. Abman SH. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 2002;87:F15-8. https://doi.org/10.1136/fn.87.1.F15
  6. An HS, Bae EJ, Kim GB, Kwon BS, Beak JS, Kim EK, et al. Pulmonary hypertension in preterm infants with bronchopulmonary dysplasia. Korean Circ J 2010;40:131-6. https://doi.org/10.4070/kcj.2010.40.3.131
  7. Kim JH, Huh J, Kang IS, Lee SI, Lee HJ, Ahn KM. Analysis of clinical course and the prognosis of pulmonary hypertension in infants with bronchopulmonary dysplasia: a single center study. Pediatr Allergy Respir Dis 2008;18:243-52.
  8. Khemani E, McElhinney DB, Rhein L, Andrade O, Lacro RV, Thomas KC, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007;120:1260-9. https://doi.org/10.1542/peds.2007-0971
  9. Kumar VH, Hutchison AA, Lakshminrusimha S, Morin FC, 3rd, Wynn RJ, Ryan RM. Characteristics of pulmonary hypertension in preterm neonates. J Perinatol 2007;27:214-9. https://doi.org/10.1038/sj.jp.7211673
  10. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009;34:1219-63. https://doi.org/10.1183/09031936.00139009
  11. De Paepe ME, Mao Q, Powell J, Rubin SE, DeKoninck P, Appel N, et al. Growth of pulmonary microvasculature in ventilated preterm infants. Am J Respir Crit Care Med 2006;173:204-11. https://doi.org/10.1164/rccm.200506-927OC
  12. Mourani PM, Mullen M, Abman SH. Pulmonary hypertension in bronchopulmonary dysplasia. Prog Pediatr Cardiol 2009;2009:43-8.
  13. Abman SH, Wolfe RR, Accurso FJ, Koops BL, Bowman CM, Wiggins JW, Jr. Pulmonary vascular response to oxygen in infants with severe bronchopulmonary dysplasia. Pediatrics 1985;75:80-4.
  14. Mourani PM, Ivy DD, Gao D, Abman SH. Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. Am J Respir Crit Care Med 2004;170:1006-13. https://doi.org/10.1164/rccm.200310-1483OC
  15. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000;279:L600-7. https://doi.org/10.1152/ajplung.2000.279.3.L600
  16. Goodman G, Perkin RM, Anas NG, Sperling DR, Hicks DA, Rowen M. Pulmonary hypertension in infants with bronchopulmonary dysplasia. J Pediatr 1988;112:67-72. https://doi.org/10.1016/S0022-3476(88)80125-2
  17. Puchalski MD, Lozier JS, Bradley DJ, Minich LL, Tani LY. Electrocardiography in the diagnosis of right ventricular hypertrophy in children. Pediatrics 2006;118:1052-5. https://doi.org/10.1542/peds.2005-2985
  18. Dabestani A, Mahan G, Gardin JM, Takenaka K, Burn C, Allfie A, et al. Evaluation of pulmonary artery pressure and resistance by pulsed Doppler echocardiography. Am J Cardiol 1987;59:662-8. https://doi.org/10.1016/0002-9149(87)91189-1
  19. Mourani PM, Sontag MK, Younoszai A, Ivy DD, Abman SH. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 2008;121:317-25. https://doi.org/10.1542/peds.2007-1583
  20. King ME, Braun H, Goldblatt A, Liberthson R, Weyman AE. Interventricular septal configuration as a predictor of right ventricular systolic hypertension in children: a cross-sectional echocardiographic study. Circulation 1983;68:68-75. https://doi.org/10.1161/01.CIR.68.1.68
  21. Nagaya N, Nishikimi T, Okano Y, Uematsu M, Satoh T, Kyotani S, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998;31:202-8.
  22. Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, et al.NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 2009;30:3-8. https://doi.org/10.1007/s00246-008-9258-4
  23. Fitzgerald DA, Massie RJ, Nixon GM, Jaffe A, Wilson A, Landau LI, et al. Infants with chronic neonatal lung disease: recommendations for the use of home oxygen therapy. Med J Aust 2008;189:578-82.
  24. Parker TA, Abman SH. The pulmonary circulation in bronchopulmonary dysplasia. Semin Neonatol 2003;8:51-61. https://doi.org/10.1016/S1084-2756(02)00191-4
  25. Balfour-Lynn IM. Domiciliary oxygen for children. Pediatr Clin North Am 2009;56:275-96 https://doi.org/10.1016/j.pcl.2008.10.010
  26. Mebazaa A, Karpati P, Renaud E, Algotsson L. Acute right ventricular failure--from pathophysiology to new treatments. Intensive Care Med 2004;30:185-96. https://doi.org/10.1007/s00134-003-2025-3
  27. Bhorade S, Christenson J, O'Connor M, Lavoie A, Pohlman A, Hall JB. Response to inhaled nitric oxide in patients with acute right heart syndrome. Am J Respir Crit Care Med 1999;159:571-9. https://doi.org/10.1164/ajrccm.159.2.9804127
  28. Banks BA, Seri I, Ischiropoulos H, Merrill J, Rychik J, Ballard RA. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics 1999;103:610-8. https://doi.org/10.1542/peds.103.3.610
  29. Kitamukai O, Sakuma M, Takahashi T, Nawata J, Ikeda J, Shirato K. Hemodynamic effects of inhaled nitric oxide using pulse delivery and continuous delivery systems in pulmonary hypertension. Intern Med 2002;41:429-34. https://doi.org/10.2169/internalmedicine.41.429
  30. Kinsella JP, Cutter GR, Walsh WF, Gerstmann DR, Bose CL, Hart C, et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 2006;355:354-64. https://doi.org/10.1056/NEJMoa060442
  31. Kinsella JP. Inhaled nitric oxide therapy in premature newborns. Curr Opin Pediatr 2006;18:107-11. https://doi.org/10.1097/01.mop.0000193291.09894.6c
  32. Ng J, Finney SJ, Shulman R, Bellingan GJ, Singer M, Glynne PA. Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafil? Br J Anaesth 2005;94:774-7. https://doi.org/10.1093/bja/aei114
  33. Max M, Rossaint R. Inhaled prostacyclin in the treatment of pulmonary hypertension. Eur J Pediatr 1999;158 Suppl 1:S23-6. https://doi.org/10.1007/PL00014316
  34. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000;35:176-82. https://doi.org/10.1016/S0735-1097(99)00494-5
  35. Ivy DD, Doran AK, Smith KJ, Mallory GB, Jr., Beghetti M, Barst RJ, et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 2008;51:161-9. https://doi.org/10.1016/j.jacc.2007.09.031
  36. Hwang SK, O YC, Kim NS, Park HK, Yum MK. Use of inhaled Iloprost in an infant with bronchopulmonary dysplasia and pulmonary artery hypertension. Korean Circ J 2009;39:343-5. https://doi.org/10.4070/kcj.2009.39.8.343
  37. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003;42:158-64. https://doi.org/10.1016/S0735-1097(03)00555-2
  38. Mourani PM, Sontag MK, Ivy DD, Abman SH. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr 2009;154:379-84, 384 e1-2. https://doi.org/10.1016/j.jpeds.2008.09.021
  39. Stewart DJ, Levy RD, Cernacek P, Langleben D. Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med 1991;114:464-9. https://doi.org/10.7326/0003-4819-114-6-464
  40. Galie N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:1380-6. https://doi.org/10.1016/S0735-1097(03)00121-9
  41. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:697-704. https://doi.org/10.1016/j.jacc.2005.01.066
  42. Krishnan U, Krishnan S, Gewitz M. Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. Pediatr Cardiol 2008;29:1082-6. https://doi.org/10.1007/s00246-008-9260-x
  43. Kim GB, Noh Cl. Intensive management of acute right heart failure. Korean J Pediatr 2007;50:1041-8. https://doi.org/10.3345/kjp.2007.50.11.1041

Cited by

  1. Pulmonary Hypertension Secondary to Bronchopulmonary Dysplasia in Very Low Birth Weight Infants (<1,500 g) vol.18, pp.1, 2011, https://doi.org/10.5385/jksn.2011.18.1.96
  2. Frontiers in pulmonary hypertension in infants and children with bronchopulmonary dysplasia vol.47, pp.11, 2010, https://doi.org/10.1002/ppul.22609
  3. Use of cardiac biomarkers in neonatology vol.72, pp.4, 2010, https://doi.org/10.1038/pr.2012.88
  4. Advances in Noninvasive Imaging in Pediatric Cardiology vol.60, pp.1, 2010, https://doi.org/10.1016/j.yapd.2013.04.002
  5. An update on pharmacologic approaches to bronchopulmonary dysplasia vol.37, pp.2, 2013, https://doi.org/10.1053/j.semperi.2013.01.008
  6. Pulmonary hypertension in bronchopulmonary dysplasia vol.37, pp.2, 2013, https://doi.org/10.1053/j.semperi.2013.01.009
  7. Health-care utilization and respiratory morbidities in preterm infants with pulmonary hypertension vol.33, pp.7, 2010, https://doi.org/10.1038/jp.2012.170
  8. Characteristics of Respiratory Distress Syndrome in Infants of Different Gestational Ages vol.191, pp.4, 2010, https://doi.org/10.1007/s00408-013-9475-3
  9. Pulmonary hypertension in bronchopulmonary dysplasia vol.100, pp.3, 2010, https://doi.org/10.1002/bdra.23241
  10. B-type natriuretic peptide and mortality in extremely low birth weight infants with pulmonary hypertension: a retrospective cohort analysis vol.14, pp.None, 2014, https://doi.org/10.1186/1471-2431-14-68
  11. Regulation of Hypoxia-induced Pulmonary Hypertension by Vascular Smooth Muscle Hypoxia-Inducible Factor-1α vol.189, pp.3, 2010, https://doi.org/10.1164/rccm.201302-0302oc
  12. Pathophysiology and Risk Factors of Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia vol.25, pp.1, 2010, https://doi.org/10.14734/kjp.2014.25.1.1
  13. Sildenafil Treatment of Infants With Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension vol.6, pp.1, 2010, https://doi.org/10.1542/hpeds.2015-0076
  14. Pulmonary hypertension in preterm infants: results of a prospective screening program vol.37, pp.5, 2010, https://doi.org/10.1038/jp.2016.255
  15. Bronchopulmonary dysplasia-associated pulmonary hypertension: clues from placental pathology vol.37, pp.12, 2010, https://doi.org/10.1038/jp.2017.130
  16. Right ventricular function in infants with bronchopulmonary dysplasia and pulmonary hypertension: a pilot study vol.9, pp.1, 2010, https://doi.org/10.1177/2045894018816063
  17. Interleukin-1 Receptor Antagonist Protects Newborn Mice Against Pulmonary Hypertension vol.10, pp.None, 2010, https://doi.org/10.3389/fimmu.2019.01480
  18. Comprehensive Evaluation of Right Heart Performance and Pulmonary Hemodynamics in Neonatal Pulmonary Hypertension : Evaluation of cardiopulmonary performance in neonatal pulmonary hypertension vol.21, pp.2, 2019, https://doi.org/10.1007/s11936-019-0713-8
  19. Pulmonary Hypertension and ATP-Sensitive Potassium Channels : Paradigms and Paradoxes vol.74, pp.1, 2010, https://doi.org/10.1161/hypertensionaha.119.12992
  20. Sildenafil for bronchopulmonary dysplasia and pulmonary hypertension: a meta‐analysis vol.9, pp.3, 2019, https://doi.org/10.1177/2045894019837875
  21. Reversibility of Pulmonary Hypertension Following Surgical Atrial Septal Defect Closure in Children with Down Syndrome vol.27, pp.4, 2010, https://doi.org/10.4250/jcvi.2019.27.e33
  22. Bronchopulmonary dysplasia vol.5, pp.1, 2010, https://doi.org/10.1038/s41572-019-0127-7
  23. Intra-tracheal administration of a naked plasmid expressing stromal derived factor-1 improves lung structure in rodents with experimental bronchopulmonary dysplasia vol.20, pp.1, 2010, https://doi.org/10.1186/s12931-019-1224-6
  24. Hyperoxia-induced lung structure–function relation, vessel rarefaction, and cardiac hypertrophy in an infant rat model vol.17, pp.None, 2019, https://doi.org/10.1186/s12967-019-1843-1
  25. Factors associated with development of early and late pulmonary hypertension in preterm infants with bronchopulmonary dysplasia vol.40, pp.1, 2020, https://doi.org/10.1038/s41372-019-0549-9
  26. Novel Strategies to Reduce Pulmonary Hypertension in Infants With Bronchopulmonary Dysplasia vol.8, pp.None, 2010, https://doi.org/10.3389/fped.2020.00201
  27. Early angiogenic proteins associated with high risk for bronchopulmonary dysplasia and pulmonary hypertension in preterm infants vol.318, pp.4, 2020, https://doi.org/10.1152/ajplung.00131.2019
  28. Pulmonary Hypertension in Children across Africa: The Silent Threat vol.2021, pp.None, 2010, https://doi.org/10.1155/2021/9998070